Hypoparathyroidism Industry Anticipated to Expand at 8.3% CAGR During the Forecast Period

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Is The Predicted Market Size Trajectory For The Hypoparathyroidism Market From 2025 To 2034?

The hypoparathyroidism market has experienced significant expansion recently. It is projected to expand from $0.95 billion in 2024 to reach $1.03 billion by 2025, demonstrating a compound annual growth rate (CAGR) of 8.6%. Historically, this expansion has been driven by factors such as the increasing occurrence of thyroid surgeries, greater public understanding of hypoparathyroidism, a rise in complications following surgery, a growing need for calcium and vitamin D supplements, and enhanced efforts in managing endocrine disorders.

The hypoparathyroidism market is anticipated to experience substantial expansion in the coming years, with its valuation projected to reach $1.42 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 8.3%. This projected growth during the forecast period is attributable to several factors, including the increasing uptake of recombinant parathyroid hormone therapies, greater investment in hypoparathyroidism research, the expansion of healthcare infrastructure, a growing elderly population susceptible to endocrine disorders, and improved awareness coupled with early diagnosis programs. Key trends anticipated during this period encompass advancements in parathyroid hormone therapies, sophisticated diagnostic methods for hypoparathyroidism, the creation of sustained-release calcium supplements, innovations in minimally invasive thyroid surgery, and enhancements in patient monitoring technologies.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24565&type=smp

Which Drivers Are Impacting The Hypoparathyroidism Market?

The rise in thyroid cancer incidents is anticipated to propel the growth of the hypoparathyroidism market. Thyroid cancer is characterized by the proliferation of abnormal cells within the thyroid gland, often manifesting as a neck lump. The increasing prevalence of thyroid cancer is attributed to enhanced diagnostic imaging technologies, which facilitate earlier and more frequent identification of small, asymptomatic thyroid nodules. This form of cancer accelerates hypoparathyroidism primarily through an increased requirement for thyroid surgeries; such procedures can inadvertently harm the parathyroid glands. This damage results in calcium imbalance and chronic hormone deficiency, thereby escalating the need for long-term disease management solutions. For instance, data from the American Cancer Society, a US-based non-profit organization, indicated in May 2024 that new thyroid cancer cases are projected to reach 44,020 in 2025, an increase from 43,720 in 2023. Consequently, the growing number of thyroid cancer cases is a key driver for the hypoparathyroidism market’s expansion.

What Are The Primary Types Of Segments Analyzed In The Hypoparathyroidism Market?

The hypoparathyroidism market covered in this report is segmented –

1) By Treatment: Hormone Replacement Therapy, Adjunctive Therapies

2) By Type: Hormone Replacement Therapy, Calcium And Vitamin D Supplements, Emerging Therapies

3) By Route Of Administration: Oral, Parenteral

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

5) By End User: Hospitals, Specialty Clinics, Homecare Settings

Subsegments:

1) By Hormone Replacement Therapy: Recombinant Parathyroid Hormone, Parathyroid Hormone Analogues, Calcimimetics, Calcium And Vitamin D Supplements

2) By Adjunctive Therapies: Magnesium Supplements, Phosphate Binders, Other Supportive Therapies

What Trends Are Expected To Drive The Hypoparathyroidism Market?

Leading companies in the hypoparathyroidism market are concentrating on developing technologically advanced products, such as those built on transition technology, to enhance the effectiveness of treatments and improve patient outcomes. TransCon technology-based products represent therapeutic solutions crafted utilizing TransCon (Transient Conjugation) technology, an exclusive platform engineered to optimize drug delivery. For example, in January 2024, Ascendis Pharma A/S, a Denmark-based biopharmaceutical company, introduced YORVIPATH (palopegteriparatide), its second product leveraging TransCon technology, in Germany and Austria for managing chronic hypoparathyroidism in adults. YORVIPATH operates as a once-daily prodrug of parathyroid hormone (PTH 1-34), formulated to maintain physiological PTH levels over 24 hours, thereby addressing the fundamental hormone deficiency characteristic of chronic hypoparathyroidism.

Who Are The Prominent Global Companies Shaping The Hypoparathyroidism Market?

Major companies operating in the hypoparathyroidism market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co Inc., AbbVie Inc., Sanofi S.A., Novartis AG, GlaxoSmithKline plc , Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Cipla Limited , Lupin Limited, Torrent Pharmaceuticals Ltd., Eagle Pharmaceuticals Inc., BridgeBio Pharma Inc., Ascendis Pharma A/S, Extend Biosciences Inc., Entera Bio Ltd.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/hypoparathyroidism-global-market-report

Which Global Regions Are Influencing The Competitive Landscape Of The Hypoparathyroidism Market?

North America was the largest region in the hypoparathyroidism market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hypoparathyroidism market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Hypoparathyroidism Market Report:

https://www.thebusinessresearchcompany.com/customise?id=24565&type=smp

Browse Through More Reports Similar to the Global Hypoparathyroidism Market 2025, By The Business Research Company

Homeopathy Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/homeopathy-global-market-report

Thyroid Function Test Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/thyroid-function-test-global-market-report

Anti Thyroid Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/anti-thyroid-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795